{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T01:47:56Z","timestamp":1785721676454,"version":"3.56.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T00:00:00Z","timestamp":1572912000000},"content-version":"vor","delay-in-days":1191,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Cerulean Pharmaceuticals"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["K23-CA 187185"],"award-info":[{"award-number":["K23-CA 187185"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1093\/annonc\/mdw188","type":"journal-article","created":{"date-parts":[[2016,7,25]],"date-time":"2016-07-25T23:39:42Z","timestamp":1469489982000},"page":"1579-1585","source":"Crossref","is-referenced-by-count":50,"title":["Efficacy of the nanoparticle\u2013drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I\u2013IIa clinical trial"],"prefix":"10.1016","volume":"27","author":[{"given":"S.M.","family":"Keefe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hoffman-Censits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.B.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Mamtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Heitjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Eliasof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Nixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Turnbull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.G.","family":"Garmey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Gunnarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Waliki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ciconte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Jayaraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Senderowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.B.","family":"Tellez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hennessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Piscitelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Vaughn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.B.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1093\/annonc\/mdw188_bb0010","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"issue":"6 Pt 1","key":"10.1093\/annonc\/mdw188_bb0015","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1097\/01.ju.0000096060.92397.ed","article-title":"The genetic basis of cancer of the kidney","volume":"170","author":"Linehan","year":"2003","journal-title":"J Urol"},{"key":"10.1093\/annonc\/mdw188_bb0020","unstructured":"National Cancer Institute. Drugs Approved in Kidney Cancer. Bethesda, MD: National Cancer Institute, http:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/kidney (1 September 2015, date last accessed)."},{"key":"10.1093\/annonc\/mdw188_bb0025","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1603018113","article-title":"CRLX101 nanoparticles localize in human tumors andnot in adjacent, nonneoplastic tissue after intravenous dosing","author":"Clark","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"issue":"37","key":"10.1093\/annonc\/mdw188_bb0030","doi-asserted-by":"crossref","first-page":"15127","DOI":"10.1073\/pnas.1309566110","article-title":"Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle","volume":"110","author":"Eliasof","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1093\/annonc\/mdw188_bb0035","doi-asserted-by":"crossref","first-page":"e10522","DOI":"10.1371\/journal.pone.0010522","article-title":"Inhibition of hypoxia-inducible factor-1alpha (HIF-1alpha) protein synthesis by DNA damage inducing agents","volume":"5","author":"Lou","year":"2010","journal-title":"PLoS One"},{"key":"10.1093\/annonc\/mdw188_bb0040","unstructured":"Ceruleanrx IB, www.ceruleanrx.com."},{"issue":"4","key":"10.1093\/annonc\/mdw188_bb0045","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1158\/1078-0432.CCR-14-2810","article-title":"Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer.","volume":"21","author":"Pham","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1093\/annonc\/mdw188_bb0050","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1093\/annonc\/mdw188_bb0055","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1007\/s10637-012-9921-8","article-title":"First-in-human phase 1\/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies","volume":"31","author":"Weiss","year":"2013","journal-title":"Invest New Drugs"},{"issue":"9637","key":"10.1093\/annonc\/mdw188_bb0060","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"issue":"7","key":"10.1093\/annonc\/mdw188_bb0065","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nrclinonc.2012.64","article-title":"Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia","volume":"9","author":"Rapisarda","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdw188_bb0070","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1158\/1535-7163.MCT-09-0274","article-title":"Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition","volume":"8","author":"Rapisarda","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"19","key":"10.1093\/annonc\/mdw188_bb0075","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMra0706596","article-title":"Tumor angiogenesis","volume":"358","author":"Kerbel","year":"2008","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1093\/annonc\/mdw188_bb0080","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-11-0682","article-title":"Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1\u03b1 in advanced solid tumors","volume":"17","author":"Kummar","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1093\/annonc\/mdw188_bb0085","doi-asserted-by":"crossref","first-page":"6845","DOI":"10.1158\/0008-5472.CAN-04-2116","article-title":"Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts","volume":"64","author":"Rapisarda","year":"2004","journal-title":"Cancer Res"},{"issue":"1","key":"10.1093\/annonc\/mdw188_bb0090","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cncr.11474","article-title":"A phase II study of irinotecan in patients with advanced renal cell carcinoma","volume":"98","author":"Fizazi","year":"2003","journal-title":"Cancer"},{"issue":"2","key":"10.1093\/annonc\/mdw188_bb0095","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s12032-011-9829-8","article-title":"A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802","volume":"29","author":"Haas","year":"2012","journal-title":"Med Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdw188_bb0100","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.clgc.2013.04.014","article-title":"High-dose bevacizumab in the treatment of patients with advanced clear cell renal carcinoma: a phase II trial of the Sarah Cannon Oncology Research Consortium","volume":"11","author":"Hainsworth","year":"2013","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1093\/annonc\/mdw188_bb0105","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S1470-2045(14)70030-0","article-title":"Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial","volume":"15","author":"Motzer","year":"2014","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1093\/annonc\/mdw188_bb0110","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1093\/annonc\/mdw188_bb0115","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw188_bb0120","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.tps4579","article-title":"Randomized phase 2 study to assess the safety and efficacy of CRLX101 in combination with bevacizumab in patients (pts.) with metastatic renal cell carcinoma (RCC) versus standard of care (SOC)","volume":"33","author":"Voss","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419347295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419347295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/27\/8\/1579\/19446683\/mdw188.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T07:55:08Z","timestamp":1624694108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419347295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S0923753419347295"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdw188","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]}}}